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Ara h: Arachis hypogaea
EC50: Half maximal effective concentration
MAT: Mast cell activation test
OFC: Oral food challenge
ROC: Receiver operating characteristic
SPT: Skin prick test
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2 HEMMINGS ET ALsensitized to but tolerant of peanut, and children who were
neither sensitized nor allergic to peanut. Levels of specific IgE to
peanut and individual allergens were quantified by using
ImmunoCAP. ImmunoCAP inhibition experiments and mast
cell activation tests in response to both Ara h 2 and Ara h 6 were
performed. Statistical analyses were done using SPSS version 14
and Prism version 7 software.
Results: Ara h 2–specific IgE and Ara h 6–specific IgE showed
the greatest diagnostic accuracy for peanut allergy when
compared with specific IgE to peanut and other peanut
allergens. Most patients with peanut allergy were sensitized to
both Ara h 2 and Ara h 6. Ara h 2 reduced Ara h 2–specific IgE
binding more than Ara h 6 did (P < .001), whereas Ara h
6–specific IgE binding was inhibited to a similar degree by Ara
h 2 and Ara h 6 (P5 .432). In the mast cell activation test, Ara h
2 induced significantly greater maximal reactivity (P 5 .001)
and a lower half maximal effective concentration (P 5 .002)
than did Ara h 6 when testing cosensitized individuals.
Conclusions: Ara h 2–specific IgE and Ara h 6–specific IgE
provide the greatest accuracy to diagnose peanut allergy. Ara h
2 is the dominant conglutin in peanut allergy in the United
Kingdom, despite a degree of cross-reactivity with Ara h 6. (J
Allergy Clin Immunol 2020;nnn:nnn-nnn.)
Key words: Ara h 2, Ara h 6, specific IgE, mast cell activation test,
ImmunoCAP inhibition, peanut allergy, cross-reactivity
Peanut allergy is a prominent IgE-mediated food allergy that
has garnered substantial clinical attention owing to the severity of
reactions and the increasing prevalence and rates of anaphylaxis.1
Peanut allergy affects about 25% of children with food allergy in
the United States. Althoughmany food allergies are transient with
age, peanut allergy appears to be particularly persistent.2 Because
of the systemic nature of peanut allergy, its symptoms can beman-
ifested in several organs, including in the oral, cutaneous, gastro-
intestinal, cardiovascular, and respiratory systems, potentially
leading to fatal reactions.
Detection of allergen-specific IgE supports the diagnosis of
peanut allergy; however, sensitization alone is not predictive. In
the United Kingdom, 11.8% of school-aged children have detect-
able levels of peanut–specific IgE; however, only 2.6% of these
children are genuinely allergic when challenged.3 The utility of
allergen-specific IgE assays to diagnose peanut allergy has
improved with the analysis of IgE to individual allergen compo-
nents. A total of 16 peanut allergens have been identified from
Arachis hypogaea 1 (Ara h 1) to Ara h 17, excluding only Ara h
4, which was initially established with unique nomenclature
before being relegated as anAra h 3 isoform (3.02).4,5Among pea-
nut components, there are 2 cupins (Ara h 1 and Ara h 3), 3 con-
glutins (Ara h 2, Ara h 6, and Ara h 7), 1 profilin (Ara h 5), 1
PR-10 protein (Ara h 8), 4 oleosins (Ara h 10, Ara h 11, Ara h
14, and Ara h 15), 3 non-specific lipid transfer proteins (Ara h 9,
Ara h 16, and Ara h 17), and 2 defensins (Ara h 12 and Ara h 13).
Ara h 1, Ara h 2, and Ara h 3 were initially identified as the
major peanut allergens, with 97% of patients with peanut allergy
sensitized to at least 1 of these allergens.6 These were also the
peanut components that offered greatest discrimination between
individuals with and without peanut allergy; in particular, Ara h
2–specific IgE has notably improved the diagnostic accuracy of
peanut allergy.7,8 More recently, Ara h 6 has also been identifiedas a major peanut allergen.9-11 Both Ara h 2 and Ara h 6 are 2S
albumins, have similar molecular weights (17 kDa and 15 kDa
respectively), share approximately 60% sequence identity, and
are expressed at similar levels across numerous peanut vari-
eties.11,12 The latter fact results in comparable levels of exposure
to both Ara h 2 and Ara h 6 when individuals with allergy
consume peanuts. Even though only the structure of the
protease-resistant core of Ara h 6 has been solved,13 it appears
that Ara h 6 and Ara h 2 are conformationally similar. Both peanut
2S albumins are resistant to high temperatures and proteolytic
digestion, and they are considered the peanut allergens with the
greatest ability to induce effector cell activation.9,14,15 Clinically,
Ara h 2 and Ara h 6 sensitization in individuals with peanut al-
lergy is associated with more severe forms of peanut allergy.16
Given the sequential and structural similarities between Ara h 2
and Ara h 6, we aimed to assess the relative importance of Ara h 2
and Ara h 6 in peanut allergy, their possible cross-reactivity, and
the utility of specific IgE to these allergens to diagnose peanut
allergy.METHODS
Study population
Individuals whowere (1) allergic to peanuts, (2) sensitized to but tolerant of
peanut, or (3) neither sensitized nor allergic to peanuts and enrolled into the
study ‘‘DiagnosticMarkers of Clinical Allergy versus Sensitization to Peanut’’
were evaluated. Peanut allergy was determined by a positive oral food
challenge (OFC) result, except in the case of patients who had a convincing
clinical history of systemic allergic reactions within 1 year of sample drawing,
together with a skin prick test (SPT) wheal size of 8 mm or greater and/or a
peanut-specific IgE titer of 15 kUA/L or greater.
17 Peanut tolerance was
defined by a negative OFC result or the ability to ingest 4 g or more of peanut
protein twice aweekwithout demonstrating an allergic response, as monitored
by a validated peanut consumption questionnaire.18 Peanut sensitization was
determined by an SPT wheal size of 1 mm or greater and/or a peanut-
specific IgE titer of 0.1 kUA/L or greater. A total of 100 patients were selected
purely on the basis of availability of serum samples of sufficient volume. The
study and the use of samples were approved by the South East London
Research Ethics Committee 2, and written informed consent was obtained
from the parents of all of the children.Allergen-specific IgE measurements
Levels of specific IgE to peanut and peanut components Ara h 1, Ara h 2,
Ara h 3, Ara h 6, Ara h 8, and Ara h 9 were quantified in patient plasma by
using the ImmunoCAP assay (Thermo Fisher, Uppsala, Sweden) and the
Phadia 100 analyzer according to the manufacturer’s instructions. Quantifi-
cation of IgE to Ara h 1, Ara h 2, Ara h 3, Ara h 8, andAra h 9was performed at
the time of recruitment and IgE to Ara h 6 at a later time, when the test became
commercially available. Any values that indicated a specific IgE level greater
than 100 kUA/L were diluted with specific IgE diluent (Thermo Fisher) 1 in 10
and retested.
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to the manufacturer’s instructions. The arrays were visualized by using a
LuxScan 10K scanner (Core Life Sciences, Irvine, Calif) and analyzed by
using Phadia Microarray Image Analysis software.Peanut allergens
For ImmunoCAP inhibition and the mast cell activation test (MAT), the
peanut allergens Ara h 2 and Ara h 6 were purchased from Indoor
Biotechnologies (Cardiff, United Kingdom). Both Ara h 2 and Ara h 6 were
purified natively from peanut kernels by using a combination of affinity and
high-performance liquid chromotography. Neither allergen showed contam-
ination with any other peanut allergens (Ara h 1, Ara h 2, Ara h 3, Ara h 6, and
Ara h 8), and contamination with each other was minimal (<_0.0005% possible
contamination of Ara h 2 with Ara h 6 and possible contamination <_0.007% of
Ara h 6 with Ara h 2 were reported) (see Table E1 in this article’s Online
Repository at www.jacionline.org).ImmunoCAP inhibition
ImmunoCAP inhibition assays were performed to establish the dominant
allergen in Ara h 2– and Ara h 6–dual-sensitized individuals. The samples
used in Ara h 2 inhibition assays were selected according to the following
criteria: dual sensitization to Ara h 2 and Ara h 6, Ara h 2–specific IgE of
>40 kUA/L, and sufficient sample volume. Of these 15 samples, 10 were
available in volumes sufficient for subsequent Ara h 6 inhibition assays.
Before assay, 75 mL of patient sera were incubated for 1 hour at room tem-
perature with 75 mL of 1 mg/mL of native Ara h 2 or 1 mg/mL of native
Ara h 6 (both from Indoor Biotechnologies, Cardiff) or PBS. Patient
plasma, which was reported to have a level of Ara h 2–specific IgE greater
than 200 kUA/L (n 5 2) in prior analyses, required an initial dilution by
half in PBS before the aforementioned allergen/PBS preincubation step
to ensure that results would be reported within the assays’ measuring
range. Preincubated samples were then assayed for Ara h2– and Ara h
6–specific IgE by using ImmunoCAP technology, as already described.
Results were expressed as specific IgE concentrations (kUA/L) alongside
the uninhibited (PBS) control.MAT
LAD2 cells, a human mast cell line that was originally isolated from the
marrow of a patient suffering with mastocytosis and is named after the
National Insitute of Health’s Laboratory of Allergic Diseases,19 were cultured
in recombinant IL-4 for 5 days before overnight sensitization with patient’s
plasma, as previously described.20,21 Serial dilutions (0.1-1000 ng/mL) of
the native peanut allergens Ara h 2 or Ara h 6 (Indoor Biotechnologies) or pea-
nut extract were added to sensitized cells and incubated for 1 hour at 37C to
induce stimulation. Cells were then assessed for surface expression of CD63
by flow cytometry. Anti-IgE (1 mg/mL) and ionomycin (1 mg/mL) were
used as IgE-mediated and non–IgE-mediated positive controls, respectively,
and 0.04% BSA RPMI medium alone was used as a negative control. Flow
cytometry was performed on a FACS Canto II with FACSDiva software
(BD Biosciences), and the data were analyzed by using FlowJo software,
version 7.6.1 (TreeStar).Statistical analysis
Comparisons of unpaired and paired continuous variables were undertaken
by using theMann-WhitneyU test andKruskal-WallisP test, respectively. The
diagnostic performance of specific IgE to peanut extract and to allergen com-
ponents was examined against the allergic status to peanut by using receiver
operating characteristic (ROC) curve analyses. Optimal cutoff values were
generated by determining theYouden index as follows: Sensitivity – (1 – Spec-
ificity). Statistical analyses were performed by using GraphPad Prism 7.0
(GraphPad Software, Inc, San Diego, Calif) and SPSS 25.0 (IBM Inc,
Armonk, NY) software.RESULTS
Study participants
A total of 100 children (50 with peanut allergy, 40 who were
sensitized to but tolerant of peanut, and 10 who were neither
sensitized nor allergic to peanut) were included in this study; they
ranged in age from 5 months to 17 years, and 69 of them were
male. The diagnosis of peanut allergy and determination of
sensitization were carried out according to the criteria previously
described.22 The children with peanut allergy were slightly older
than the children who were sensitized to but tolerant of peanut,
and they had largerwheals on the SPTand higher levels of specific
IgE to peanut Ara h 2, Ara h 3, and Ara h 6, with a large overlap
between the 2 groups. Total IgE level was higher in the group of
those who were sensitized to but tolerant of peanut. The demo-
graphic, clinical, and serologic features of the study population
are shown in Table I.Specific IgE to Ara h 2 and Ara h 6 are the best
serologic markers to diagnose peanut allergy
Levels of specific IgE to peanut (P5 .019), Ara h 2 (P < .001),
Ara h 3 (P 5 .046), and Ara h 6 (P < .001) were all significantly
higher in children with peanut allergy than in individuals sensi-
tized to but tolerant of peanut. Conversely, Ara h 1–, Ara h 8–,
and Ara h 9–specific IgE were not able to discriminate between
those individuals in this population who had peanut allergy and
those who were sensitized to but tolerant of peanut (Fig 1).
The diagnostic utility of each serologic marker was assessed by
using ROC curve analyses (Fig 2). The areas under the ROC curve
for Ara h 2–specific IgE (0.916) and Ara h 6–specific IgE (0.908)
were far greater than the area under the ROC curve for IgE to pea-
nut or any of the other allergen specificities assessed (see Table E2
in this article’s Online Repository at www.jacionline.org).
Following the initial analyses, optimal cutoffs for Ara h 2–specific
IgE (0.28 kUA/L) and Ara h 6–specific IgE (0.32 kUA/L) were
generated. They both reported 82% sensitivity, but the cutoff for
Ara h 2–specific IgE had 94% specificity to diagnose peanut al-
lergy and the cutoff for Ara h 6–specific IgE had 90% specificity.The majority of patients with peanut allergy are
cosensitized to Ara h 2 and Ara h 6
Considering the similarities in sequence and structure between
Ara h 2 and Ara h 6 molecules, wewanted to assess which of the 2
allergens was dominant in our patient population. Most in-
dividuals sensitized to peanut were sensitized to both Ara h 2
and Ara h 6. For instance, Ara h 2 and Ara h 6 sensitization was
seen in 61 of 90 individuals (68%) and 55 of 90 individuals (61%)
sensitized to peanut, respectively, with 49 of 90 individuals (54%)
reporting Ara h 2 and Ara h 6 cosensitization. As shown in Fig 3,
A-C, in the group of children sensitized to but tolerant of peanut,
there was no significant difference between Ara h 2–specific IgE
andAra h 6–specific IgE levels (P5.084). However, for the group
of those with peanut allergy, the levels of Ara h 2–specific IgE
were significantly higher than the levels of Ara h 6–specific IgE
(P < .001), suggesting Ara h 2 as the dominant allergen. This
skewing of IgE sensitization toward Ara h 2 also appears to be
true across the whole study population, in which the significant
difference remains (P < .001) (see Fig E1 in this article’s
Online Repository at www.jacionline.org). Despite this, a strong
FIG 1. Distribution of specific IgE (sIgE) levels in individuals with peanut allergy (n 5 50), individuals
sensitized to but tolerant of peanut (n 5 40), and individuals neither sensitized nor allergic to peanut (n 5
10). The Mann-Whitney U test was used for the comparison between individuals with peanut allergy and
individuals sensitized to but tolerant of peanut. *P < .05; **P < .01; ***P < .001; ****P < .0001.




Sensitized to but tolerant
of peanut (n 5 40)
Not allergic to
peanut (n 5 10) P value
Age (y) 8.31 (1.68-17.91) 5.93 (0.52-15.81) 5.96 (0.77-12.58) .003
Males 36 (72%) 25 (62.5%) 8 (80%) .371
Result of SPT to peanut (mm) 9 (1-34)* 3 (0-12)* 0 (0-0) <.0001
Total IgE level (kUA/L) 297.5 (4-3550) 469 (7-10714) 29.5 (6-397) .5757
Level of specific IgE to peanut (kUA/L) 12 (0.2-568) 2.41 (0.04-128) 0.01 (0-0.9) .0019
Level of specific IgE to Ara h 1 (kUA/L) 0.8 (0-199) 0.11 (0-88.3) 0 (0-0.01) .0838
Level of specific IgE to Ara h 2 (kUA/L) 2.54 (0.01-278) 0.07 (0-82.3) 0.04 (0.01-0.07) <.0001
Level of specific IgE to Ara h 3 (kUA/L) 0.36 (0-89.6) 0.06 (0-7.28) 0.01 (0-0.04) .0456
Level of specific IgE to Ara h 6 (kUA/L) 3.835 (0-155) 0.03 (0-86) 0(0-0.02) <.0001
Level of specific IgE to Ara h 8 (kUA/L) 0.09 (0-185) 0.04 (0-88.6) 0 (0-0.02) .4022
Level of specific IgE to Ara h 9 (kUA/L) 0.02 (0-871) 0.05 (0-43.9) 0.01 (0-0.02) .0834
Values are expressed as number (%) or median (range). P value refers to the comparison between patients with peanut allergy and patients sensitized to but tolerant of peanut using
Mann-Whitney U test.
*SPT result for 49 children with peanut allergy and 38 children who were sensitized to but tolerant of peanut.
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6–specific IgE levels (r 5 0.8791), as seen in Fig 4.
In this study, 2 individuals (4%) from the group with peanut
allergy (n5 50) showed detectable levels of specific IgE to Ara h
6 (>_0.1) but remained unsensitized for Ara h 2 (<0.1) (see Table
E3 in this article’s Online Repository at www.jacionline.org).
Of these, only 1 individual (patient 164) reported genuine mono-
sensitization to Ara h 6 (ie, this individual did not have detectable
IgE for any of the other peanut components [considering single-
plex ImmunoCAP]). Peanut allergy in this patient was confirmed
by OFC. Subsequent investigations of this patient’s sample led toImmunoCAP ISAC analyses, which, however, indicated sensiti-
zation to both Ara h 2 (0.6 ISAC standardized units) and Ara h
6 (0.8 ISAC standardized units) but not to any of the other 110 al-
lergens present in that assay.IgE of Ara h 2– and Ara h 6–dual-sensitized
individuals predominantly binds Ara h 2
Of the 50 individuals with peanut allergy who were included in
this study, 42 (84%) were sensitized to both Ara h 2 and Ara h 6,
with 31 of 42 (74%) reporting higher levels of Ara h 2–specific
FIG 2. ROC curves for IgE specific to peanut (purple), Ara h 1 (red), Ara h 2 (orange), Ara h 3 (green), Ara h 6
(blue), Ara h 8 (pink), and Ara h 9 (yellow) across the entire study population (N 5 100). For areas under the
ROC curves and the respective 95% CIs, see Table E2. sIgE, Specific IgE.
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between Ara h 2 and Ara h 6 binding, we performed ImmunoCAP
inhibition experiments examining binding to Ara h 2 and Ara h 6
by using samples from 15 dual-sensitized individuals with peanut
allergy (Table II). In these experiments, IgE binding to both Ara h
2 and Ara h 6 was assessed following preincubation of sera, in a
1:1 ratio, with PBS, Ara h 2, or Ara h 6.
Inhibition of Ara h 2 binding assays demonstrated that
preincubation of sera with Ara h 2 (P < .001) or Ara h 6
(P < .001) was able to significantly block binding of IgE to
Ara h 2, in comparison with the PBS controls (Fig 5, A).
Notably, Ara h 2 preincubation led to a significantly greater in-
hibition of Ara h 2 binding than Ara h 6 (P < .001). Ara h 6
binding following preincubation with either Ara h 2
(P 5 .002) and Ara h 6 (P 5 .002) showed significant inhibi-
tion (Fig 5, B). However, preincubation with Ara h 2 inhibited
IgE binding to the Ara h 6 ImmunoCAP to a degree similar to
that with preincubation with Ara h 6. These data suggest that
Ara h 2 is the dominant allergen in Ara h 2– and Ara h
6–dual-sensitized individuals.Ara h 2 induces greater effector cell activation than
Ara h 6 in Ara h 2– and Ara h 6–dual-sensitized
individuals with peanut allergy
To relate Ara h 2 and Ara h 6 IgE binding to functional effector
cell activation following stimulation with allergen, we took the
same 10 dual-sensitized individuals with peanut allergy as
assessed in the Ara h 2 and Ara h 6 inhibition experiments and
performed MAT assays against both Ara h 2 and Ara h 6 across a
range of concentrations.MAT analyses showed that Ara h 2 was able to induce a
significantly greater proportion of activated mast cells (defined as
percentage of CD631 LAD2 cells in relation to the negative con-
trol) than Ara h 6 at 0.1 ng/mL (P5 .033), 1 ng/mL (P <.001), 10
ng/mL (P 5 .005), 100 ng/mL (P 5 .013), and 1000 ng/mL (P <
.001) of allergen (see Fig 6, A). Sensitivity and reactivity of the
LAD2 cells in response to both allergens were also assessed.
All half maximal effective concentration (EC50) values were
calculated for both Ara h 2 and Ara h 6 dose responses, with
Ara h 6 stimulation showing a significantly greater EC50 (P 5
.002) (see Fig 6, B). The maximal reactivity (greatest percentage
of CD631 activation) was significantly higher for Ara h 2 than for
Ara h 6 in these dual-sensitized individuals (P < .01) (see Fig 6,
C). Cosensitization to Ara h 2 and Ara h 6 was associated with
a higher proportion of activated mast cells (see Fig E2 in this ar-
ticle’s Online Repository at www.jacionline.org).DISCUSSION
Ara h 2 and Ara h 6 share sequence and structural similarities,
and the majority of patients with peanut allergy are sensitized to
Ara h 2. In this study, we confirmed that Ara h 6 is also a major
peanut allergen in our patient population. Although most patients
were cosensitized to both Ara h 2 and Ara h 6, levels of Ara h 6–
specific IgE were generally lower in patients with peanut allergy,
and the degree of IgE inhibition to both allergens was higher
following preincubation with Ara h 2 than with Ara h 6,
suggesting that Ara h 2 is the dominant allergen. Ara h 2 was a
more efficient inducer of effector cell activation than Ara h 6 was.
We evaluated the diagnostic utility of specific IgE to Ara h 6 in a
large cohort of children being assessed for peanut allergy and
FIG 3. Paired Ara h 2–specific IgE and Ara h 6–specific IgE levels across individuals with peanut allergy (A)
(n5 50; P < .001), individuals sensitized to but tolerant of peanut (B) (n540; P5 .240), and individuals neither
sensitized nor allergic to peanut (C) (n5 10; P5 .004). The Wilcoxon signed rank test was used for the com-
parison between Ara h 2–specific and Ara h 6–specific IgE levels, *P < .05; **P < .01; *** P < .001; **** P <
.0001. ns, Not significant; sIgE, specific IgE.
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FIG 4. Correlation between specific IgE (sIgE) to Ara h 2 and Ara h 6 across
the whole study population; individuals with peanut allergy (n 5 50 [red]);
individuals sensitized to but tolerant of peanut (n 5 40 [blue]); and individ-
uals who were neither allergic nor sensitized to peanut (n 5 10 [green]).
Spearman correlation test; R 5 0.8791.
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reliably used in the United Kingdom and other areas with similar
populations of patients with peanut allergy. A level of specific IgE
to Ara h 6 greater or equal than 0.32 kUA/L confirms peanut al-
lergy with 82% sensitivity and 90% specificity, with Ara h 2–spe-
cific IgE greater or equal to 0.26 kUA/L improving specificity
slightly (94%) with the exact same sensitivity; thus, Ara h 2–spe-
cific IgE captures more cases with peanut allergy, and Ara h 6–
specific IgE is rarely needed as an additional test for peanut
allergy.
To our knowledge, this is the largest study assessing the
diagnostic performance of Ara h 6–specific IgE in the singleplex
ImmunoCAP assay and the first in the United Kingdom. Ara h 2
has long been considered the best marker for peanut allergy in
both adult and pediatric patients, and this was reflected in our
population.7,8,23 Ara h 6, most likely because of its sequential and
structural similarity, has been reported alongside Ara h 2 as an
important marker for peanut allergy, both serologically and as
an inducer of effector cell response.9-11,16,24 In our cohort, we
confirmed that Ara h 6 is a major allergen in the United Kingdom.
However, the higher levels of Ara h 2–specific IgE and the greater
IgE-inhibitory capacity of Ara h 2 suggest Ara h 2 dominance
when compared with Ara h 6. The majority of our patients with
peanut allergy (84%) were cosensitized to both Ara h 2 and Ara
h 6, and only a minority were monosensitized to either Ara h 6
(4%) or Ara h 2 (8%). A case series recently published by van
der Valk et al highlighted the clinical importance, albeit uncom-
monness, of monosensitization to Ara h 6 and related it to moder-
ate to severe allergic reactions to peanut.25 Only 1 individual with
peanut allergy in our cohort was monosensitized to Ara h 6 on the
basis of initial ImmunoCAP testing; however, genuine monosen-
sitization is dubitable following subsequent ImmunoCAP ISAC
analyses that reported sensitization to both Ara h 2 and Ara h 6,
with higher levels of Ara h 6–specific IgE than Ara h 2–specific
IgE. Despite the generally low levels of specific IgE, an OFC
was performed in this individual and confirmed peanut allergy.In this instance, another characteristic of IgE, such as IgE affinity,
as opposed to titer and specificity, may be more influential in trig-
gering the allergic response by mast cells and basophils.
Identifying the dominant 2S albumin between Ara h 2 and Ara
h 6 is always likely to be complicated by the structural and/or
binding similarities, with 41 shared epitopes previously identified
between the 2 allergens.26 However, the Ara h 2 and Ara h 6 aller-
gens used had minimal, if any, contamination with each other.
Herein, we adapted methods of IgE inhibition from Amoah
et al to test our hypotheses.27 However, in contrast to that study,
we utilized the technique on an individual patient basis rather
than pooled sera. This is the first data of its type assessing Ara
h 2 and Ara h 6 competition in individuals with peanut allergy.
The incorporation of ImmunoCAP technology into the inhibition
experiments allowed for fully quantitative IgE measurements,
highly sensitive detection of changes in specific IgE concentra-
tion, and also reproducibility in other patient populations, which
is a particular strength of the ImmunoCAP technology. We noted,
however, some technical variation in the levels with samples be-
ing selected on the basis of having levels higher than 40 kUA/L
and showing (in a 1:1 dilution) levels below 20 kUA/L, but thema-
jority of these samples showed levels very close to 20 kUA/L after
dilution, and this variation would not have affected the results, as
inhibition was expressed in relation to the respective PBS control,
which was tested simultaneously. Inhibition experiments revealed
Ara h 2 as the dominant inhibitory allergen, demonstrating an
ability to reduce IgE binding to both Ara h 2 and Ara h 6 to a
significantly greater degree than Ara h 6 did. This is consistent
with previous data from our own laboratory and with data pub-
lished by Bernard et al, in which additional linear epitope(s)
that were identified on native Ara h 2, and not conserved within
native Ara h 6, may offer unique binding sites.28,29 The additional
linear epitope(s) on Ara h 2 is likely to increase the binding of Ara
h 2–specific IgE. Notably, however, both Ara h 2 and Ara h 6 were
able to inhibit IgE binding to each other, suggesting that Ara h
2– and Ara h 6–specific IgE in patients with peanut allergy is a
mix of IgE resulting from primary sensitization and cross-
reactivity, concordant with data recently published by
Hazebrouck et al.30 Both these data and our results presented
here suggest variability among individuals, with different propor-
tions of IgE antibodies binding uniquely or cross-reactively toAra
h 2 and Ara h 6. These observations led us to perform functional
MATs in the dual-sensitized individuals for whom both Ara h 2
and Ara h 6 inhibition experiments were undertaken. Similarly,
Ara h 2 induced activation to a greater degree in these individuals,
even though both allergens were able to generate a substantial
response. The distinctive biologic activity can be better high-
lighted through comparison of both the EC50 values andmaximal
reactivity. Ara h 2 dose responses generated significantly lower
EC50 values, but significantly greater maximum reactivity, in
the same dual-sensitized individuals. In other words, lower con-
centrations of Ara h 2 were needed to cause similar effector cell
activation, with Ara h 2 inducing a larger proportion of activated
mast cells than Ara h 6 did. Monosensitization to either Ara h 2 or
Ara h 6 was associated with a lower degree of mast cell activation
to peanut than was cosensitization to Ara h 2 and Ara h 6. Given
that greater mast cell activation is associated with more severe re-
actions, being cosensitized to both allergens could convey a
higher risk of anaphylaxis.21
Overall, our data showed that independent as well as cross-
reactive sensitizations to Ara h 2 and Ara h 6 are present in
TABLE II. Demographic and serologic features of individuals whose samples were used in Ara h 2 inhibition (n 5 15), Ara h 6






























018 6.95 F 20 1872 466 109 144 7.41 79.5 0.07 1.05
020* 15.93 F 34 542 90.5 48 80 10.3 27.8 8.47 0.01
041 17.91 F 10 430 159 36.9 96.5 2.41 52.6 0.01 0.01
083* 6.45 M 14 799 163 27.9 65.5 32.3 56.4 0.11 0.47
090* 5.94 M 12 928 135 71.7 54.4 1.33 27.8 0.08 0.08
096* 15.91 M 22 328 139 39.9 68.1 3.59 43.6 0.24 0
101* 4.22 M 10 76 62.1 18.5 42 0.2 6.84 0 0
103* 16.90 M 7 906 82.1 3.57 54.6 7.62 46.4 11.3 0.14
108 8.97 M 7 874 254 59.5 117 61.5 23.2 0.32 0.04
112* 14.54 M 14 823 197 33.5 90.7 31.6 23.5 4.6 0.3
119* 8.33 M 10 3531 568 199 278 89.6 73.2 0.1 0.1
122 6.01 M 13 545 175 51.2 78.4 11 59.3 4.53 5.62
125* 10.38 M 14 3383 515 189 160 76.1 80.9 0.17 1.16
134 11.50 F 19 496 205 97.7 70.3 36.6 20.6 0.15 0.06
184* 7.74 F 4 1796 455 75.4 252 64.8 155 0.05 0.06
F, Female; ID, identifier; M, male.
*Peanut allergic patients tested on Ara h 6 inhibition assay and the mast cell activation tests to Ara h 2 and Ara h 6.
FIG 5. Inhibition of IgE binding to Ara h 2 (A) and Ara h 6 (B) following preincubation of serum with PBS
(control), Ara h 2, or Ara h 6. The Wilcoxon signed rank test was used for the comparison between bound
Ara h 2–specific IgE (sIgE) and Ara h 6–specific IgE. *P < .05; **P < .01; ***P < .001; ****P < .0001. sIgE, Spe-
cific IgE.
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8 HEMMINGS ET ALdual-sensitized individuals but indicated that Ara h 2 is likely the
dominant allergen in our population of United Kingdom–based
children. Hence, we consider Ara h 2–specific IgE the most
important diagnostic marker in peanut allergy even if Ara h6–specific IgE levels may need to be determined in rare individual
cases. As well as confirming Ara h 2 as the most dominant peanut
allergen and demonstrating its superior diagnostic accuracy, our
study may inform future allergen-specific immunotherapy (AIT)
FIG 6. A, Results of the MAT to both Ara h 2 and Ara h 6 in children with peanut allergy (n5 10). Increasing
concentrations of allergen from 0.01 ng/mL to 1000 ng/mL and 1 mg/mL of anti-IgE were used to stimulate
LAD2 cells previously sensitized with the patient’s plasma. A paired t test was used to compare the percent-
age of CD631 LAD2 cells between Ara h 2 and Ara h 6. B, Comparison of LAD2 (percentage of CD63 cells)
EC50 in response to Ara h 2 and Ara h 6 stimulation in dual-sensitized patients (P 5 .002 with the Wilcoxon
signed rank test). C, Comparison of paired maximal reactivity in response to Ara h 2 and Ara h 6 stimulation
in dual-sensitized patients (P < .01 with the Wilcoxon signed rank test). *P < .05; **P < .01; ***P < .001;
****P < .0001. sIgE, Specific IgE.
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potential as disease-modifying therapy, with large numbers of
individuals undergoing treatment reporting reduced symptoms
and increased levels of peanut-specific IgG4.31,32 Being the most
important elicitors of peanut allergic reactions, Ara h 2 and Ara h
6 may also be the key peanut allergens to use for AIT. Although
immunotherapy can induce changes in levels of IgE and IgG4 to
different peanut allergens, a recent study showed that changes
in antibody titer in response to peanut AIT were predominantly
to Ara h 2– and Ara h 6–specific IgE and IgG4, with significant
increases in Ara h 2 and Ara h 6 IgG4/IgE ratios, highlighting
the importance of these 2 allergens in peanut allergy, which is
consistent with our findings.33-36 We believe that if food AIT,
like diagnostics, becomes more targeted to specific allergens
over the coming years, the best candidates for peanut AIT could
be Ara h 2 and Ara h 6. This is concordant with previous data
generated in a study by Kulis et al, in which a combinatory Ara
h 2 and Ara h 6 immunotherapy protocol was able to significantly
reduce symptoms and functional cell activation in allergic mouse
models.37 Despite our data suggesting that Ara h 2 alonewould be
sufficient to diagnose peanut allergy in the majority of individ-
uals, the presence of both independent and cross-reactive Ara h
2– and Ara h 6–specific IgE antibodies in most individuals with
peanut allergy illustrates the potential benefit of combinatory
Ara h 2 and Ara h 6 therapy.
We are indebted to the patients and families who participated in the
study and to the clinical team recruiting and assessing patients, including
doctors, nurses and dietitians of the Children’s Allergy Service of Evelina
London Children’s Hospital and the SEAL Research Trials Unit.
Furthermore, we would like to extend our thanks to Jonas Lindholm
and Magnus Borres of Thermofisher for reviewing the article before
submission.Clinical implications: Ara h 2 is the dominant allergen and a
more potent elicitor of mast cell activation than Ara h 6 is. Spe-
cific IgE to Ara h 2 is sufficient to diagnose peanut allergy in the
majority of patients.REFERENCES
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FIG E1. Paired Ara h 2– and Ara h 6–specific IgE (sIgE) levels across the
whole study population (N5 100). The Wilcoxon signed rank test was used
for the comparison between Ara h 2–and Ara h 6– specific IgE levels (P <
.0001). sIgE, Specific IgE.
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FIG E2. Results of theMAT to peanut in individuals with peanut allergy (n5
48). Individuals were stratified by monosensitization to Ara h 2 or Ara h 6 or
cosensitization to both allergens.
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TABLE E1. Percentage contamination of Ara h 2 and Ara h 6 with other peanut allergens
Allergen
Contamination (%)
Ara h 1 Ara h 2 Ara h 3 Ara h 6 Ara h 8
Ara h 2 0 — 0.007 0.0005 0.0003
Ara h 6 0 0.007 0 — 0
Data are as provided and performed by Indoor Biotechnologies as part of the quality control procedure. Results have been generated by using ELISA.
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TABLE E2. Performance of specific IgE to peanut and individual peanut allergens in the diagnosis of peanut allergy, as governed
by area’s under the Receiver Operator Characteristic curve (AUC)
Marker AUC 95% CI Cutoff (kUA/L) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Peanut-specific IgE 0.752 0.658-0.845 21.25 32.29 93.1 92 36
Ara h 1-specific IgE 0.668 0.559-0.777 2.68 32.86 90 88.46 36.49
Ara h 2-specific IgE 0.916 0.857-0.975 0.28 82 94 93.18 83.93
Ara h 3-specific IgE 0.672 0.563-0.78 1.1 33.33 87.1 85.19 36.99
Ara h 6-specific IgE 0.908 0.846-0.97 0.32 82 90 89.13 83.33
Ara h 8-specific IgE 0.624 0.511-0.737 0.015 60 31.43 61.9 29.73
Ara h 9-specific IgE 0.468 0.354-0.581 0.86 14.58 82.69 43.75 51.19
AUC, Area under the curve; NPV, negative predictive value; PPV, positive predictive value.
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Ara h 1 sIgE
level (kUA/L)
Ara h 2 sIgE
level (kUA/L)
Ara h 3 sIgE
level (kUA/L)
Ara h 6 sIgE
level (kUA/L)
Ara h 8 sIgE
level (kUA/L)
Ara h 9 sIgE
level (kUA/L)
087 5.78 M 6 540 2.7 0.02 0.06 0.11 0.14 1.2 8.1
164 1.68 M 4 6.36 0.46 0.01 0.01 0.01 0.88 0.02 0.01
ID, Identifier; M, male; sIgE, specific IgE.
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